Updated Results From DREAMM-3, a Phase 3 Study of Belantamab Mafodotin (Belamaf) Versus Pomalidomide Plus Dexamethasone in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM)

被引：0

作者：

Hungria, Vania T. M. ^{[1
]}

Weisel, Katja ^{[2
]}

Radinoff, Atanas ^{[3
]}

Delimpasi, Sosana ^{[4
]}

Mikala, Gabor ^{[5
]}

Masszi, Tamas ^{[6
]}

Li, Jian ^{[7
]}

Capra, Marcelo ^{[8
]}

Maiolino, Angelo ^{[9
]}

Pappa, Vasiliki ^{[10
]}

Chraniuk, Dominik ^{[11
]}

Osipov, Iurii ^{[12
]}

Leleu, Xavier ^{[13
]}

Low, Michael ^{[14
]}

Kouri, Fotini ^{[15
]}

Liboon, John ^{[16
]}

Brawley, Chris ^{[17
]}

Lewis, Eric ^{[18
]}

Tubel, Gabriela

Li, Mary ^{[18
]}

McKeown, Astrid

Roy-Ghanta, Sumita ^{[18
]}

Opalinska, Joanna ^{[18
]}

Dimopoulos, Meletios ^{[19
]}

机构：

[1] Clin Sao Germano Sao Paulo, Dept Hematol, Sao Paulo, Brazil

[2] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany

[3] Univ Hosp St Ivan Rilski EAD, Dept Clin Hematol, Sofia, Bulgaria

[4] Gen Hosp Evangelismos, Athens, Greece

[5] Natl Inst Haematol & Infect Dis, Dept Hematol & Stem Cell Transplantat, South Pest Cent Hosp, Budapest, Hungary

[6] Semmelweis Univ, Dept Internal Med & Hematol, Budapest, Hungary

[7] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Hematol, Beijing, Peoples R China

[8] Hosp Mae Deus, Ctr Integrado Hematol Oncol, Porto Alegre, RS, Brazil

[9] Inst Amer Ensino Pesquisa & Inovacao, Rio De Janeiro, Brazil

[10] Univ Gen Hosp Attikon, Hematol Unit, Dept Internal Med & Res Unit 2, Athens, Greece

[11] Wojewodzki Szpital Zespolony, Dept Hematol, Torun, Poland

[12] VA Almazov Natl Med Res Ctr, St Petersburg, Russia

[13] CHU Poitiers, PRC, Hematol, Poitiers, France

[14] Clayton Univ, Monash Univ, Monash Hlth, Monash Haematol, Clayton, Vic, Australia

[15] GSK, Stevenage, Herts, England

[16] GSK, San Diego, CA USA

[17] GSK, London, England

[18] GSK, Upper Providence, PA USA

[19] Natl & Kapodistrian Univ Athens, Sch Med, Dept Clin Therapeut, Athens, Greece

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-395

引用

页码：S261 / S262

页数：2

共 50 条

[41] Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Overall Survival Results from the Phase 3 Apollo Study
Dimopoulos, Meletios A.
Terpos, Evangelos
Boccadoro, Mario
Delimpasi, Sosana
Beksac, Meral
Katodritou, Eirini
Moreau, Philippe
Baldini, Luca
Symeonidis, Argiris
Bila, Jelena
Oriol, Albert
Mateos, Maria-Victoria
Einsele, Hermann
Orfanidis, Ioannis
Kampfenkel, Tobias
Liu, Weiping
Kosh, Michele
NamPhuong Tran
Carson, Robin
Sonneveld, Pieter
BLOOD, 2022, 140 : 7272 - 7274
[42] Characterization of Ocular Adverse Events in Patients Receiving Belantamab Mafodotin (Belamaf) for ≥12 Months: Post Hoc Analysis of DREAMM-2 Study in Relapsed/Refractory Multiple Myeloma (RRMM)
Lonial, Sagar
Nooka, Ajay K.
Thulasi, Praneetha
Badros, Ashraf Z.
Jeng, Bennie H.
Callander, Natalie S.
Sborov, Douglas
Zaugg, Brian E.
Popat, Rakesh
Degli Esposti, Simona
Baron, January
Doherty, Allison
Lewis, Eric
Opalinska, Joanna
Paka, Prani
Piontek, Trisha
Gupta, Ira
Farooq, Asim V.
Jakubowiak, Andrzej
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S419 - S419
[43] DREAMM-5 platform trial: Belantamab mafodotin in combination with novel agents in patients with relapsed/refractory multiple myeloma (RRMM).
Richardson, Paul G.
Biswas, Swethajit
Holkova, Beata
Jackson, Nicola
Netherway, Thelma
Paul, Sofia
Ferron-Brady, Geraldine
Yeakey, Anne
Shelton, Chris
de Oca, Rocio Montes
Ahlers, Christoph Matthias
Ballas, Marc S.
Paul, Elaine Marie
Gupta, Ira
Opalinska, Joanna
Luptakova, Katarina
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[44] Safety and clinical activity of belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM): DREAMM-6 arm-A interim analysis.
Quach, Hang
Gironella, Mercedes
Lee, Cindy
Popat, Rakesh
Cannell, Paul
Kasinathan, Ravi
Chopra, Bikramjit
Rogers, Rachel
Ferron-Brady, Geraldine
Shafi-Harji, Seema
Patel, Nashita
Opalinska, Joanna
Gupta, Ira V.
Augustson, Bradley
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[45] APOLLO: Phase 3 randomized study of subcutaneous Daratumumab plus Pomalidomide and Dexamethasone (D-Pd) versus Pomalidomide and Dexamethasone (Pd) alone in patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Einsele, H.
Dimopoulos, M.
Terpos, E.
Boccadoro, M.
Delimpasi, S.
Beksac, M.
Katodritou, E.
Moreau, P.
Baldini, L.
Symeonidis, A.
Bila, J.
Oriol, A.
Mateos, M. -, V
Orfanidis, I
Ahmadi, T.
Ukropec, J.
Kampfenkel, T.
Schecter, J.
Qiu, Y.
Amin, H.
Vermeulen, J.
Carson, R.
Sonneveld, P.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 178 - 178
[46] DREAMM-5 platform trial: Belantamab mafodotin (belamaf; GSK2857916) in combination with five different novel agents in patients with relapsed/refractory multiple myeloma (RRMM)
Richardson, Paul G.
Trudel, Suzanne
Callander, Natalie S.
Nooka, Ajay
Song, Kevin
Uttervall, Katarina
Minnema, Monique C.
Rodriguez-Otero, Paula
Struemper, Herbert
Yeakey, Anne
de Oca, Rocio Montes
Smith, L. Mary
Jackson, Nicola
Kaisermann, Morrys
Im, Ellie
Basile, Frank G.
Ahlers, Christoph M.
Holkova, Beata
Gupta, Ira
Kremer, Brandon E.
Quach, Hang
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S156 - S156
[47] DREAMM-2: Single-Agent Belantamab Mafodotin (Belamaf) Effects on Patient-Reported Outcome (PRO) Measures in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Popat, Rakesh
Lonial, Sagar
Voorhees, Peter M.
Degli Esposti, Simona
Gupta, Ira
Opalinska, Joanna
Sapra, Sandhya
Gorsh, Boris
He, Zangdong
Kleinman, David M.
Schaumberg, Debra
Loubert, Angely
Meunier, Juliette
Regnault, Antoine
Eliason, Laurie
BLOOD, 2020, 136
[48] A PHASE IB STUDY OF ISATUXIMAB PLUS POMALIDOMIDE (POM) AND DEXAMETHASONE (DEX) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
Mikhael, J.
Richardson, P.
Usmani, S.
Raje, N.
Bensinger, W.
Kanagavel, D.
Gao, L.
Ziti-ljajic, S.
Anderson, K.
HAEMATOLOGICA, 2017, 102 : 168 - 168
[49] Characterization of ocular adverse events in patients receiving belantamab mafodotin (belamaf) for ≥12 months: post-hoc analysis of DREAMM-2 study in relapsed/refractory multiple myeloma (RRMM)
Trautmann-Grill, K.
Lonial, S.
Nooka, A. K.
Thulasi, P.
Badros, A. Z.
Jeng, B. H.
Callander, N. S.
Sborov, D.
Zaugg, B. E.
Popat, R.
Degli, Esposti S.
Baron, J.
Doherty, A.
Lewis, E.
Opalinska, J.
Paka, P.
Piontek, T.
Gupta, I
Farooq, A., V
Jakubowiak, A.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 181 - 181
[50] Patient-reported outcomes (PROs) from the DREAMM-7 randomized phase 3 study comparing belantamab mafodotin, bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in patients with relapsed/refractory multiple myeloma (RRMM)
Hungria, Vania
Robak, Pawel
Hus, Marek
Fu, Chengcheng
Zherebtsova, Vera
Ward, Christopher
De Almeida, Ana Carolina
Ho, P. Joy
Hajek, Roman
Cerchione, Claudio
Pirooz, Nicholas
McKeown, Astrid
Baig, Hena
Eccersley, Lydia
Pompilus, Farrah
McNamara, Simon
Lin, Chee Paul
Roy-Ghanta, Sumita
Opalinska, Joanna
Mateos, Maria-Victoria
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

← 1 2 3 4 5 →